• We provide you with scientifically substantiated
    answers to regulatory questions.

  • Use our data-based status quo analysis
    to develop your strategy.

  • Polynomics = economic expertise
    + many years of industry experience.

Latest News

Oncology. Between regulation and patient use [20.11.2020]

As instructed by Bristol Myers Squibb, we have studied cancer and the progress of cancer treatments.

Social costs of addiction [17.11.2020]

On behalf of the FOPH, we have assessed the costs of addiction in Switzerland.

Impact of choice of the percentile in Hospital benchmarking [22.07.2020]

On commission of the VZK we analyse the impact of choice of the percentile in in benchmarking of the acute stationary hospitals.